Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Article activity feed

1. Version published to 10.1016/j.apsb.2020.04.008

   Jul 1, 2020
2. 

   ScreenIT

   Jun 4, 2020

   SciScore for 10.1101/2020.02.27.20027557: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: The study procedure was approved by Animal Ethics Committee of Guangzhou Medical University. IRB: The Ethics Committee from Dawu County People’s Hospital approved the study.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	Six-week old female mice were intravenous injected with VSV (108 PFU/g) and followed with DIP (35 mg/kg; intraperitoneal injection, i.p; twice/day) treatment for 5 days.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   After 24 hours of incubation, cells were fixed and permeabilized with Cytofix/Cytoperm (BD), incubated with a rabbit anti-HCoV-19 …

   SciScore for 10.1101/2020.02.27.20027557: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: The study procedure was approved by Animal Ethics Committee of Guangzhou Medical University. IRB: The Ethics Committee from Dawu County People’s Hospital approved the study.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	Six-week old female mice were intravenous injected with VSV (108 PFU/g) and followed with DIP (35 mg/kg; intraperitoneal injection, i.p; twice/day) treatment for 5 days.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   After 24 hours of incubation, cells were fixed and permeabilized with Cytofix/Cytoperm (BD), incubated with a rabbit anti-HCoV-19 nucleocapsid protein polyclonal antibody (Sino Biological), followed by a HRP-labelled goat anti-rabbit secondary antibody (Jackson).	a rabbit suggested: None nucleocapsid protein polyclonal antibody ( Sino Biological) , followed by a HRP-labelled goat anti-rabbit secondary antibody ( Jackson) suggested: None anti-rabbit suggested: None
   The antibodies against TBK1 [TBK1/NAK (D1B4	TBK1 suggested: (Cell Signaling Technology Cat# 3504, RRID:AB_2255663)
   Experimental Models: Cell Lines
   Sentences	Resources
   Fluorescent focus assay: Vero E6 cells were seeded in 96-well plates and treated with different dosages of dipyridamole or chloroquine for an hour before infected with HCoV-19.	Vero E6 suggested: None
   Experimental Models: Organisms/Strains
   Sentences	Resources
   VSV-induced viral pneumonia model: C57/BL-6J mice were obtained from the Guangdong Medical Laboratory Animal Center.	C57/BL-6J suggested: None
   Software and Algorithms
   Sentences	Resources
   DIP (PubChem CID: 3108	PubChem suggested: (PubChem, RRID:SCR_004284)
   Statistical analysis: Statistical analyses and graphics production were performed using R v3.5.3 (Foundation for Statistical Computing) and GraphPad Prism 8.	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.02.27.20027557 on medRxiv

   Feb 29, 2020